Fyremadel
FYREMADEL- ganirelix acetate injection, solution
Ferring Pharmaceuticals Inc.
FOR SUBCUTANEOUS USE ONLY
Rx only
DESCRIPTION
FYREMADEL (ganirelix acetate) injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix acetate is derived from native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, 8, and 10 to form the following molecular formula of the peptide: N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N9 ,N10 -diethyl-D-homoarginyl-L-leucyl-N9 ,N10 -diethyl-L-homoarginyl-L-prolyl-D-alanylamide acetate. The molecular weight for ganirelix acetate is 1570.4 as an anhydrous free base. The structural formula is as follows:
Ganirelix Acetate
FYREMADEL (ganirelix acetate) injection is supplied as a colorless, sterile, ready-to-use, aqueous solution intended for SUBCUTANEOUS administration only. Each single-dose, sterile, prefilled syringe contains 250 mcg/0.5 mL of ganirelix acetate, 0.1 mg glacial acetic acid, 23.5 mg mannitol, and water for injection adjusted to pH 5 with acetic acid and/or sodium hydroxide.
CLINICAL PHARMACOLOGY
The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient rises in serum LH. At midcycle, a large increase in GnRH release results in an LH surge. The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. Luteinization results in a rise in serum progesterone with an accompanying decrease in estradiol levels.
Ganirelix acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by ganirelix acetate is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix acetate, which is consistent with an antagonist effect. Upon discontinuation of ganirelix acetate, pituitary LH and FSH levels are fully recovered within 48 hours.
Pharmacokinetics
The pharmacokinetic parameters of single and multiple injections of ganirelix acetate injection in healthy adult females are summarized in Table I. Steady-state serum concentrations are reached after 3 days of treatment. The pharmacokinetics of ganirelix acetate are dose-proportional in the dose range of 125 mcg to 500 mcg.
tmax h | t1/2 h | Cmax ng/mL | AUCng∙h/mL | CL/FL/h | Vd /FL | |
---|---|---|---|---|---|---|
tmax Time to maximum concentrationt1/2 Elimination half-lifeCmax Maximum serum concentrationAUC Area under the curve; Single dose: AUC0–∞ ; multiple dose: AUC0–24 Vd Volume of distributionCL Clearance = Dose/AUC0–∞ F Absolute bioavailability | ||||||
| ||||||
Ganirelix Acetate single dose | 1.1 (0.3) | 12.8 (4.3) | 14.8 (3.2) | 96 (12) | 2.4 (0.2)* | 43.7 (11.4)* |
Ganirelix Acetate multiple dose | 1.1 (0.2) | 16.2 (1.6) | 11.2 (2.4) | 77.1 (9.8) | 3.3 (0.4) | 76.5 (10.3) |
Absorption
Ganirelix acetate is rapidly absorbed following subcutaneous injection with maximum serum concentrations reached approximately one hour after dosing. The mean absolute bioavailability of ganirelix acetate following a single 250 mcg subcutaneous injection to healthy female volunteers is 91.1%.
Distribution
The mean (SD) volume of distribution of ganirelix acetate in healthy females following intravenous administration of a single 250 mcg dose is 43.7 (11.4) liters (L). In vitro protein binding to human plasma is 81.9%.
Metabolism
Following single-dose intravenous administration of radiolabeled ganirelix acetate to healthy female volunteers, ganirelix acetate is the major compound present in the plasma (50 to 70% of total radioactivity in the plasma) up to 4 hours and urine (17.1 to 18.4% of administered dose) up to 24 hours. Ganirelix acetate is not found in the feces. The 1 to 4 peptide and 1 to 6 peptide of ganirelix acetate are the primary metabolites observed in the feces.
Excretion
On average, 97.2% of the total radiolabeled ganirelix acetate dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [14 C]-ganirelix acetate. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.
Special Populations
The pharmacokinetics of ganirelix acetate injection have not been determined in special populations such as geriatric, pediatric, renally impaired and hepatically impaired patients (see PRECAUTIONS).
Drug-Drug Interactions
Formal in vivo or in vitro drug-drug interaction studies have not been conducted (see PRECAUTIONS). Since ganirelix acetate can suppress the secretion of pituitary gonadotropins, dose adjustments of exogenous gonadotropins may be necessary when used during controlled ovarian hyperstimulation (COH).
Clinical Studies
The efficacy of ganirelix acetate injection was established in two adequate and well-controlled clinical studies which included women with normal endocrine and pelvic ultrasound parameters. The studies intended to exclude subjects with polycystic ovary syndrome (PCOS) and subjects with low or no ovarian reserve. One cycle of study medication was administered to each randomized subject. For both studies, the administration of exogenous recombinant FSH [Follistim® 1 (follitropin beta for injection)] 150 IU daily was initiated on the morning of Day 2 or 3 of a natural menstrual cycle. Ganirelix acetate injection was administered on the morning of Day 7 or 8 (Day 6 of recombinant FSH administration). The dose of recombinant FSH administered was adjusted according to individual responses starting on the day of initiation of ganirelix acetate. Both recombinant FSH and ganirelix acetate were continued daily until at least three follicles were 17 mm or greater in diameter at which time hCG [Pregnyl® 1 (chorionic gonadotropin for injection, USP)] was administered. Following hCG administration, ganirelix acetate and recombinant FSH administration were discontinued. Oocyte retrieval, followed by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), was subsequently performed.
In a multicenter, double-blind, randomized, dose-finding study, the safety and efficacy of ganirelix acetate injection were evaluated for the prevention of LH surges in women undergoing COH with recombinant FSH. Ganirelix acetate injection doses ranging from 62.5 mcg to 2,000 mcg and recombinant FSH were administered to 332 patients undergoing COH for IVF (see TABLE II). Median serum LH on the day of hCG administration decreased with increasing doses of ganirelix acetate. Median serum E2 (17β-estradiol) on the day of hCG administration was 1,475; 1,110; and 1,160 pg/mL for the 62.5 mcg, 125 mcg, and 250 mcg doses, respectively. Lower peak serum E2 levels of 823, 703, and 441 pg/mL were seen at higher doses of ganirelix acetate 500 mcg, 1,000 mcg, and 2,000 mcg, respectively. The highest pregnancy and implantation rates were achieved with the 250 mcg dose of ganirelix acetate injection as summarized in Table II.
Daily Dose (mcg) of Ganirelix Acetate Injection | ||||||
---|---|---|---|---|---|---|
62.5 mcg | 125 mcg | 250 mcg | 500 mcg | 1,000 mcg | 2,000 mcg | |
(Protocol 38602) | ||||||
No. subjects receiving ganirelix acetate | 31 | 66 | 70 | 69 | 66 | 30 |
No. subjects with ET * | 27 | 61 | 62 | 54 | 61 | 27 |
No. of subjects with LH rise ≥ 10 mIU/mL † | 4 | 6 | 1 | 0 | 0 | 0 |
Serum LH (mIU/mL) on day of hCG ‡ 5th to 95th percentiles | 3.60.6 to 19.9 | 2.50.6 to 11.4 | 1.7< 0.25 to 6.4 | 10.4 to 4.7 | 0.6< 0.25 to 2.2 | 0.3< 0.25 to 0.8 |
Serum E2 (pg/mL) on day of hCG ‡ 5th to 95th percentiles | 1,475645 to 3,720 | 1,110424 to 3,780 | 1,160 384 to 3,910 | 823279 to 2,720 | 703284 to 2,360 | 441166 to 1,940 |
Vital pregnancy rate § | ||||||
per attempt, n (%) | 7 (22.6) | 17 (25.8) | 25 (35.7) | 8 (11.6) | 9 (13.6) | 2 (6.7) |
per transfer, n (%) | 7 (25.9) | 17 (27.9) | 25 (40.3) | 8 (14.8) | 9 (14.8) | 2 (7.4) |
Implantation rate (%)¶ | 14.2 (26.8) | 16.3 (30.5) | 21.9 (30.6) | 9 (23.7) | 8.5 (21.7) | 4.9 (20.1) |
Transient LH rises alone were not deleterious to achieving pregnancy with ganirelix acetate at doses of 125 mcg (3/6 subjects) and 250 mcg (1/1 subjects). In addition, none of the subjects with LH rises ≥ 10 mIU/mL had premature luteinization indicated by a serum progesterone above 2 ng/mL.
A multicenter, open-label, randomized study was conducted to assess the efficacy and safety of ganirelix acetate injection in women undergoing COH. Follicular phase treatment with ganirelix acetate 250 mcg was studied using a luteal phase GnRH agonist as a reference treatment. A total of 463 subjects were treated with ganirelix acetate by subcutaneous injection once daily starting on Day 6 of recombinant FSH treatment. Recombinant FSH was maintained at 150 IU for the first 5 days of ovarian stimulation and was then adjusted by the investigator on the sixth day of gonadotropin use according to individual responses. The results for the ganirelix acetate arm are summarized in Table III.
Ganirelix Acetate 250 mcg | |
---|---|
(Protocol 38607) | |
No. subjects treated | 463 |
Duration of GnRH analog (days)*† | 5.4 (2) |
Duration of recombinant FSH (days)*† | 9.6 (2) |
Serum E2 (pg/mL) on day of hCG ‡ 5th to 95th percentiles | 1,190373 to 3,105 |
Serum LH (mIU/mL) on day of hCG ‡ 5th to 95th percentiles | 1.60.6 to 6.9 |
No. of subjects with LH rise ≥ 10 mIU/mL § | 13 |
No. of follicles > 11 mm *† | 10.7 (5.3) |
No. of subjects with oocyte retrieval | 440 |
No. of oocytes † | 8.7 (5.6) |
Fertilization rate | 62.1% |
No. subjects with ET ¶ | 399 |
No. of embryos transferred † | 2.2 (0.6) |
No. of embryos † | 6 (4.5) |
Ongoing pregnancy rate #* | |
per attempt, n (%)Þ | 94 (20.3) |
per transfer, n (%) | 93 (23.3) |
Implantation rate (%)† | 15.7 (29) |
Some centers were limited to the transfer of ≤ 2 embryos based on local practice standards The mean number of days of ganirelix acetate treatment was 5.4 (2 to 14).
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.